Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

New England Journal of Medicine

Volumn 340, Issue 15, 1999, Pages 1137-1143

  Morris, Mitchell ^b   Eifel, Patricia J ^c   Lu, Jiandong ^c   Grigsby, Perry W ^c   Levenback, Charles ^c   Stevens, Randy E ^c   Rotman, Marvin ^c   Gershenson, David M ^c   Mutch, David G ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; MITOMYCIN; PACLITAXEL;

ADULT; ARTICLE; BLADDER DISEASE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; TREATMENT OUTCOME; TUMOR VOLUME; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AORTA; BRACHYTHERAPY; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PELVIS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0033561204     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904153401501     Document Type: Article

References (31)

1. Landis SH, Murray T, Boldcn S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29. [Erratum, CA Cancer J Clin 1998;48: 192.]
2. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16.
3. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer 1990;65:2507-14.
4. Delgado G, Bundy BN, Fowler WC Jr, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;35:314-20.
5. Alvarez RD, Soong SJ, Kinney WK, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol 1989;35:130-5.
6. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991;67:2776-85.
7. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: ten-year treatment results of RTOG 79-20. JAMA 1995; 274:387-93.
8. Thomas G, Dembo A, Fyles A, et al. Concurrent chemoradiation in advanced cervical cancer. Gynecol Oncol 1990;38:446-51.
9. Grigsby PW, Graham MV, Perez CA, Galakatos AE, Camel HM, Kao MS. Prospective phase I/II studies of definitive irradiation and chemotherapy for advanced gynecologic malignancies. Am J Clin Oncol 1996;19:1-6.
10. Stehman FB, Bundy BN, Thomas G, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993;11:1523-8.
11. Bauer M, Leibel S, Wasserman T, et al. Effect of misonidazole dose on survival in patients with stage IIIB-IVA squamous cell carcinoma of the uterine cervix: an RTOG randomized trial. Int J Radiat Oncol Biol Phys 1986;12:1101-3.
12. International Federation of Gynecology and Obstetrics. Staging announcement: FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995;5:319.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
15. Kalbfleisch ID, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:167-9.
16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
17. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
18. Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1990;46:81-92.
19. Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW III, Shingleton HM, Blessing JA. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 1979;5:317-22.
20. Thomas G, Dembo A, Beale F, et al. Concurrent radiation, mitomycin C and 5-fluorouracil in poor prognosis carcinoma of cervix: preliminary results of a phase I-II study. Int J Radiat Oncol Biol Phys 1984;10:1785-90.
21. John M, Flam M, Caplan R, et al. Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecol Oncol 1996;61:221-6.
22. Corn BW, Micaily B, Dunton CJ, et al. Concomitant irradiation and dose-escalating carboplatin for locally advanced carcinoma of the uterine cervix: an updated report. Am J Clin Oncol 1998;21:31-5.
23. Chen MD, Paley PJ, Potish RA, Twiggs LB. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 1997;67:131-6.
24. Lanciano RM, Won M, Coia LR, Hanks GE. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 Patterns of Care studies. Int J Radiat Oncol Biol Phys 1991;20:667-76.
25. Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25:273-9.
26. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
27. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
28. Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D, Weiss L. Weekly cisplatin and radical radiation therapy for advanced, recurrent, and poor prognosis cervical carcinoma. Cancer 1993;71:3703-6.
29. Fields AL, Anderson PS, Goldberg GL, et al. Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix. Gynecol Oncol 1996;61:416-22.
30. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
31. Grigsby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1998;41:817-22.